PatientFinder is an analytics tool that assesses local markets for expansion opportunity by determining the number of insured patients in each territory who have a specific disease but are untreated. It is the only burden of disease database for prevalence and treated rates at the local level—all 317 MSAs and 50 states.

Questions answered include:
  • Which states and metropolitan statistical areas have the greatest number of patients with insurance?
  • How many patients have the disease but are not treated in each territory?
  • How many insured patients would be gained in each local market if territories with poor treatment rates were brought up to the national average?
PatientFinder provides:
  • Disease-specific prevalence numbers for each U.S. state and metropolitan statistical area
  • Examination of treatment rates for the disease population to create percent treated and percent untreated estimates by state and metropolitan statistical area
  • Unique analysis of the untreated population examined through a filter of Rx benefit coverage. The end result is an estimate of how many patients are untreated but can afford therapy within each territory—the true local measure of opportunity for pharma companies
PatientFinder is the first burden of disease data set that reveals true market expansion opportunity at a local level. It will provide the following information for each of the 50 states and 318 metropolitan statistical areas:

  • Population breakdown by age, gender,race and socioeconomic status
  • Insured population
  • Uninsured as percent of population
  • Insured with Rx benefit
Disease Insight
  • Prevalence of disease
  • Prevalence as percent of population
  • Treated for disease
  • Treated as percent of population
  • Untreated for disease
  • Untreated as percent of population
  • Untreated with Rx benefit
With this information, pharmaceutical organizations can identify the local markets that offer the greatest opportunity for their branded drug. Companies can identify markets that are underserved and determine if they should increase direct-to-consumer advertising, work with the local managed care organization to increase awareness of the disease and benefits of their drug or align reps to maximize market potential.